泽璟制药：关于自愿披露注射用ZGGS34获得药物临床试验批准通知书的公告

Group 1 - The core point of the article is that Zai Lab has received approval from the National Medical Products Administration for the clinical trial of ZGGS34, which is intended for MUC17 positive advanced solid tumors [2] Group 2 - The approval signifies a significant step forward for Zai Lab in its oncology pipeline, potentially enhancing its market position in the treatment of advanced solid tumors [2]